Macro International Ltd

Astal Laboratories Ltd announced outcomes from its board meeting held on June 29, 2026. The board has authorized Mr. Sudheer Karna Kankanala, Whole-time Director, to explore and negotiate the acquisition of USFDA/EU-GMP/WHO-GMP compliant pharmaceutical manufacturing units in India. This strategic move aims to expand manufacturing capacity and strengthen global market presence. Additionally, Mr. Balayogiswara Rao Peddinti, CFO, is authorized to raise up to ₹300 Crore through various convertible and non-convertible instruments via private placement, subject to approvals. The meeting commenced at 10:00 AM and concluded at 10:48 AM.

Astal Laboratories Ltd. has authorized key managerial personnel (KMPs) to determine the materiality of events and make necessary disclosures to the stock exchange under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The authorized KMPs include Sudheer Karna Kankanala (Whole-time director & CFO) and the Company Secretary & Compliance Officer, with their respective contact details provided.

Astal Laboratories Ltd has re-appointed M/s V R P S & Co. Chartered Accountants as Internal Auditors for the financial year 2026-27. The decision was made during the Board of Directors meeting held on May 30, 2026. This re-appointment is in compliance with the Companies Act 2013 and SEBI (LODR) Regulations, 2015.

Astal Laboratories Ltd has announced the approval of its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results at their meeting held on May 30, 2026. The auditors' report has an unmodified opinion on the financial results. The results are available on the company's website.

Astal Laboratories Ltd announced audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board of Directors approved these results on May 30, 2026. Revenue from operations for FY26 stood at ₹155.19 million, with a net profit of ₹108.66 million. The auditor's report has an unmodified opinion. The company focuses on manufacturing Pharmaceutical Ingredients (Bulk Drugs).

Astal Laboratories Ltd's board meeting on May 30, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board also approved the re-appointment of M/s V R P S & Co. Chartered Accountants as Internal Auditors for the F.Y. 2026-27. The meeting commenced at 5:00 P.M. and concluded at 7:20 P.M.

Astal Laboratories Ltd has allotted 1,13,300 equity shares with a face value of ₹10 each at an issue price of ₹40 each (including a premium of ₹30 per share) upon the conversion of warrants. These warrants were part of a preferential issue of 37,29,930 warrants allotted on November 27, 2024. The allotment was approved at a board meeting held on May 25, 2026. Post allotment, the paid-up equity capital of the company has increased from ₹436,856,320.00 to ₹437,989,320.00.

Astal Laboratories Ltd announced the lapse and forfeiture of 1,86,700 convertible warrants, initially allotted on November 27, 2024, due to non-receipt of the balance 75% consideration within the stipulated 18-month period, which expired on May 26, 2026. Consequently, the upfront subscription amount of ₹18,67,000 (25% of the issue price) has been forfeited, in accordance with SEBI ICDR Regulations. The warrant holders will no longer have rights to convert these warrants into equity shares. The company's paid-up share capital remains unchanged, and the forfeited amount will be retained and accounted for as per applicable accounting standards. This will be discussed in the upcoming board meeting.

Astal Laboratories Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider the appointment of an Internal Auditor for the Financial Year 2026-27. The trading window for designated persons is closed from April 1, 2026, until 48 hours after the meeting.

Astal Laboratories Ltd's board approved the allotment of 1,13,300 equity shares with a face value of ₹10 each at an issue price of ₹40 each (including a premium of ₹30 per share). These shares were issued upon exercising the option available with warrant holders (non-promoter category) who converted warrants allotted on November 27, 2024, on a preferential basis. The paid-up equity capital increased from ₹436,856,320.00 to ₹437,989,320.00.